12:00 AM
Mar 19, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Saphris regulatory update

The Scottish Medicines Consortium recommended against the use of Sycrest asenapine from marketing partner H. Lundbeck A/S (CSE:LUN, Copenhagen, Denmark) on the National Health Service (NHS) in Scotland to treat moderate to...

Read the full 146 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >